

1210429



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

BEST AVAILABLE COPY August 27, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/487,530

FILING DATE: July 14, 2003

RELATED PCT APPLICATION NUMBER: PCT/US04/22460

Certified by

Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office



PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. RV191761629US

19589 U.S. PTO
69/487530
07/14/03

INVENTOR(S)					
Given Name (first and middle (if any))		Family Name or Surname		Residence (City and either State or Foreign Country)	
Jeffrey A. Vincent E.		Engler Escuyer		Birmingham, Alabama Birmingham, Alabama	
<input type="checkbox"/> Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
IDENTIFICATION OF REAGENTS FOR THE DIAGNOSIS AND STUDY OF FRANCISELLA					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input checked="" type="checkbox"/> Customer Number		23378		Place Customer Number Bar Code Label here	
OR		Type Customer Number here			
<input type="checkbox"/> Firm or Individual Name					
Address					
Address					
City		State	ZIP		
Country		Telephone	Fax		
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		40	<input type="checkbox"/> CD(s), Number		
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets		4	<input checked="" type="checkbox"/> Other (specify)		Fee Transmittal Sequence listing (2)
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		FILING FEE AMOUNT (\$)			
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees					
<input type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number				\$80.00	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are:					

Respectfully submitted,

SIGNATURE

Date 7-14-2003

REGISTRATION NO.

45,587

(if appropriate)

Docket Number:

PC908545006P

TYPED or PRINTED NAME T. Gregory Peterson

TELEPHONE

(205) 521-8084

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

16562 U.S. PTO
07/14/03

PTO/SB/17 (5-03)
Approved for use through 04/30/2003. OMB 0051-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) \$80.00

Complete If Known

Application Number new application
Filing Date February 14, 2003
First Named Inventor Jeffrey A. Engler
Examiner Name n/a
Group Art Unit n/a
Attorney Docket No. P69085US00GP

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit card ☐ Money ☐ Other ☐ None

☐ Deposit Account:

Deposit
Account
Number

Deposit
Account
Name

The Commissioner is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☐ Credit any overpayments

☐ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee
to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 750	2001 375	Utility filing fee	
1002 330	2002 165	Design filing	
1003 520	2003 260	Plant filing fee	
1004 750	2004 375	Reissue filing	
1005 160	2005 80	Provisional filing fee	80.00
SUBTOTAL (1)			(\$)

2. EXTRA CLAIM FEES FOR UTILITY AND

Total Claims	Extra Claims	Fee from below	Fee Paid
-20** = 0	X		0.00
Independent Claims -3** = 0	X		0.00
Multiple Dependent			

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 84	2201 42	Independent claims in excess of 3
1203 280	2203 140	Multiple dependent claim, if not paid
1204 84	2204 42	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) \$0.00

**or number previously paid, if greater. For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non - English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 410	2252 205	Extension for reply within second month	
1253 930	2253 465	Extension for reply within third month	
1254 1,450	2254 725	Extension for reply within fourth month	
1255 1,970	2255 985	Extension for reply within fifth month	
1401 320	2401 160	Notice of Appeal	
1402 320	2402 160	Filing a brief in support of an appeal	
1403 280	2403 140	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,300	2453 650	Petition to revive - unintentional	
1501 1,300	2501 650	Utility issue fee (or reissue)	
1502 470	2502 235	Design issue fee	
1503 630	2503 315	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR § 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Statement	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 750	2809 375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810 750	2810 375	For each additional invention to be examined (37 CFR § 1.129(b))	
1801 750	2801 375	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

SUBTOTAL (3) (\$) \$0.00

SUBMITTED BY

Name Gregory Peterson
Signature

Registration No. 45,587
(Attorney/Agent)

Complete (if applicable)

Telephone (205) 521-8084
Date 7-14-2003

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



ONE FEDERAL PLACE
1010 FIFTH AVENUE NORTH
BIRMINGHAM, AL 35203-2104
205.521.8000 FAX 205.521.8000
WWW.BRADLEYARANT.COM

T. Gregory Peterson, Ph.D.

July 14, 2003

Direct Dial: 205 521-8084
Direct Fax: 205 488-6084
gpeterson@bradleyarant.com

VIA EXPRESS MAIL NO. EV193763629US

Mail Stop Provisional Patent Application
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

**Re: NEW PROVISIONAL PATENT APPLICATION FOR IDENTIFICATION OF
REAGENTS FOR THE DIAGNOSIS AND STUDY OF FRANCISELLA**

Applicants:	Engler et al
Application No.:	<i>not yet assigned</i>
Filed:	July 14, 2003, by Express Mail <i>herewith</i>
Art Unit:	<i>not yet assigned</i>

Dear Sir:

Enclosed herewith are the following:

- (1) a new PROVISIONAL PATENT APPLICATION entitled "IDENTIFICATION OF REAGENTS FOR THE DIAGNOSIS AND STUDY OF FRANCISELLA", including a Specification, an Abstract, a Claim, Figures, and Sequence Listing;
- (2) an authorization to charge deposit account;
- (3) a Provisional Patent Application Transmittal; and
- (4) a Fee Transmittal.

Thank you for your cooperation and assistance in this matter. Please do not hesitate to call if you have any questions.

Yours very truly,

T. Gregory Peterson
Registration No. 45,587

July 14, 2003

Page 2

TGP/jct
Enclosures

cc: Jeffrey A. Engler, Ph.D. (with provisional application)
Vincent E. Escuyer, Ph.D. (with provisional application)
Carol Mayes (with enclosures)
Lucy Hicks, Esq. (with enclosures)

July 14, 2003

Page 3

CERTIFICATE OF EXPRESS MAILING


I hereby certify that the following items are enclosed:

1. Cover Letter (including this page) 3 pages
2. Provisional Patent Application 46 pages
38 pages specification, 1 pages claims, 1 page abstract
4 pages drawing and 2 pages sequence listing
3. Fee Transmittal 1 page
4. Provisional Application Transmittal 1 page

TOTAL of 4 Documents 51 pages

and are being deposited with the "Express Mail Post Office to Addressee" service of the United States Postal Service in an envelope marked **EV193763629US** addressed to Mail Stop Provisional Patent Application, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on July 14, 2003,


Date: 7-14-03



T. Gregory Peterson

**AUTHORIZATION TO CHARGE
DEPOSIT ACCOUNT**

I hereby authorize the Commissioner of Patents and Trademarks to charge all fees, charges, and other sums due to Deposit Account Number 50-0954.



T. Gregory Peterson

Authorized User of Deposit Account 50-0954

IDENTIFICATION OF REAGENTS FOR THE DIAGNOSIS AND STUDY OF FRANCISELLA

Inventors

Jeffrey A. Engler, Ph.D. and Vincent E. Escuyer, Ph.D.

Filed: July 14, 2003

Express Mail No. EV193763629US

Attorney Docket No.: P69085US00GP

Express Mail No: EV193763629US

IDENTIFICATION OF REAGENTS FOR THE DIAGNOSIS AND STUDY OF FRANCISELLA

Jeffrey A. Engler, Ph.D. and Vincent E. Escuyer, Ph.D.

FIELD

The present disclosure relates to the analysis of organisms causing human disease and/or posing a biological threat. Specifically, the current disclosure relates to reagents that are capable of identifying organisms causing human disease and/or posing a biological threat.

BACKGROUND

The growing concern for the use of biological agents as weapons in terrorist incidents has prompted Federal health agencies to accelerate measures to protect the public from such attacks. In February, 2002, the National Institute of Allergy and Infectious Diseases (NIAID) released its biodefense research agenda for CDC category A agents. The agenda described the high priority goals for immediate, intermediate and long-term research related to counter bioterrorism (1).

Francisella tularensis, the agent causing tularemia, is a CDC category A agent and is considered as a major biological threat. *F. tularensis* has long been considered as a potential biological weapon. In the 1950's and the 1960's, the US military developed weapons that would disseminate *F. tularensis* aerosols and by the late 1960s, *F. tularensis* was one of several biological weapons stockpiled (2). A parallel effort by Soviet Union continued into the early 1990s and resulted in weapons production of *F. tularensis* strains engineered to be resistant to antibiotics and vaccines (3). *F. tularensis* a good candidate for a biological weapon due to its very high infectivity. The infectious dose can be as low as 10 to 50 microorganisms if inhaled (4). In 1969, a World Health Organization expert committee estimated that an aerosol dispersal of 50 kg of virulent *F. tularensis* over a metropolitan area with 5 million inhabitants would result in 250,000 incapacitated casualties, including 19,000 deaths (5). Recently, the Centers for Disease Control and Prevention examined the expected economic impact of

bioterrorist attacks and estimated that the total base cost to society of an *F. tularensis* aerosol attack would be \$5.4 billion for every 100,000 persons exposed (6).

Tularemia is a zoonotic disease caused by *F. tularensis* and occurs mainly in the Northern Hemisphere (reviewed in 7). In the United States, the disease is most prevalent in Arkansas, Illinois, Missouri, Texas, Virginia and Tennessee (8). Tularemia agent is primarily recovered from lagomorphs (rabbits), rodents and arthropods (ticks and deer flies) within the United States and from water, mosquitoes and aquatic mammals outside the United States. The rabbit is the vertebrate most commonly associated with tularemia in North America. The reported incidence of tularemia in the United States since 1967 has been fewer than 200 cases per year (9). However, in the event of an intentional release, a large number of cases in a local geographical area would be expected.

Tularemia is acquired under natural conditions by direct inoculation (such as, but not limited to, arthropod bite), animal contact such as, but not limited to, skinning or eating infected animals, by drinking contaminated water, or via the airborne route (10-12). As few as 10 to 50 microorganisms given by aerosol can cause infection in humans (4). To date, tularemia transmission from patient to patient has never been reported.

Tularemia can be divided into the ulceroglandular (~75% of the patients) and the typhoidal (~25% of the patients) forms, based on the clinical symptoms. The average incubation period is 3 to 6 days. Patients with the ulceroglandular form of the disease develop nonspecific symptoms consisting of fever, chill, headache cough and myalgia (13). A cutaneous ulcer occurs, associated with large peripheral lymph nodes (> 1cm) in 60% of patients and is the most common sign of tularemia. The typhoidal form presents symptoms very similar to the ulceroglandular form, but lymph nodes are usually smaller (< 1cm) and skin lesions are generally absent. Approximately 80% of the patients with the typhoidal form also contract pneumonia; this linkage probably accounts for the higher mortality associated with this form of the disease (30-60% if untreated) (8). As a result of its higher mortality, the typhoidal form would be the most likely form in case of an act of bioterrorism.

A live attenuated vaccine has been developed from the avirulent live vaccine strain (LVS) initially used by the Russian in the 1930's (14, 15). It is used to protect people routinely working with *F. tularensis*. This vaccine has been shown to protect human volunteers against an aerosol challenge with virulent *F. tularensis* (16). Recent investigations of mouse models have suggested that the delivery site may influence the host defense mechanisms employed to combat the infection (17). The LVS is currently available as an Investigational New Drug and is under review by the US Food and Drug Administration.

Rapid diagnostic testing for tularemia is not widely available (reviewed in 41, 42). The organism can be isolated from blood, sputum, skin, or mucosal membrane lesions of an affected individual, but microbiologic diagnosis can be difficult due to unusual growth requirements for *Francisella* strains and/or due to the overgrowth of commensal bacteria. Diagnosis of primary typhoidal tularemia is also difficult because signs and symptoms are nonspecific and frequently there is no suggestive exposure history (43). Because of its infrequent occurrence, its symptoms might be misidentified, resulting in a delay in starting effective antibiotic treatment. In the case of an intentional or accidental release of aerosolized *Francisella* strains, such as, but not limited to, *F. tularensis*, it may be the clustered occurrence and unusual epidemiologic features that alert authorities to the intentional release. A number of assays may be used to identify *Francisella* strains, such as, but not limited to, *F. tularensis*, but the availability of such assays (for example, antigen detection, PCR, ELISA; compared in (44)) may only be available in research and reference laboratories. Serologic assays to detect the presence of specific antibody may not be diagnostic for many days after infection and would hinder effective treatment and/or containment of an intentional release. Any diagnostic reagent for strains of *Francisella* would be a major benefit, since the treatment for tularemia is the same for all strains (62-64). In cases of geographically concentrated outbreaks of tularemia (such as, but not limited to, but not limited to, in a biological attack, an inadvertent release or a naturally occurring outbreak), the inability to rapidly diagnose the causative *Francisella* agent could be the key impediment to an effective public health response.

Therefore, a rapid and sensitive diagnostic assay is needed to allow a rapid response in the event of an intentional or accidental release of pathogenic *Francisella* strains. Such a diagnostic assay is currently lacking in the art.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows a representative diagram of the Negative/Positive biopanning procedure used in the present disclosure. In this example, peptide sequences that bind to *F. tularensis* LVS and not to *F. philomiragia* were isolated using both negative and positive selection steps as indicated (59). Phage that did not bind *F. philomiragia* was applied to *F. tularensis* LVS and the bound phage were eluted with low pH buffer. The eluted phages were then amplified in additional rounds of selection.

FIG. 2 shows relative phage binding to *F. tularensis* LVS, *F. novicida* and *F. philomiragia*. 4-4-2 phage (expressing peptides having the sequence of TSITPWFFLSRP) (SEQ ID NO: 2) and OV1 phage (negative control, expressing peptides having the sequence of TGRHTPWPHFMP) (SEQ ID NO: 4) were used. Identical aliquots of phage were allowed to bind for 2 hours at each temperature shown. The columns show the ratio of binding to *F. tularensis* LVS and *F. novicida*, compared to *F. philomiragia* (ratio = 1). The ratios observed did not significantly change when the amount of phage added was varied from 0.1 to 100 phage added per bacterium (data not shown).

FIG. 3 shows phage binding to *F. tularensis* LVS (FT), *F. novicida* (FN), *F. philomiragia* (FP), *S. aureus* (SA), *E. coli* (EC), and *E. hirae* (ENT) at 4°C and at 37°C. 4-4-2 = 4-4-2 phage expressing peptides having the sequence of TSITPWFFLSRP) (SEQ ID NO: 2); negative = OV1 phage (expressing peptides having the sequence TGRHTPWPHFMP) (SEQ ID NO: 4).

FIG. 4 shows Trypsin sensitivity of phage binding to *F. tularensis* LVS (FT) and to *F. philomiragia* (FP) at 37°C. 4-4-2 = 4-4-2 phage expressing peptides having the sequence

of TSITPWFFLSRP) (SEQ ID NO: 2); negative = OV1 phage (expressing peptides having the sequence TGRHTPWPHFMP) (SEQ ID NO: 4).

FIG. 5 shows the specificity of phage binding to *F. tularensis* LVS and *F. novicida*. 1 x 10¹¹ bacteriophage were mixed with peptide p442 or p442S at the concentration shown and allowed to bind to 1 x 10⁹ *F. tularensis* LVS or 1 x 10⁹ *F. novicida* bacteria for 1 hour at 4°C in 1x PBS. After binding, bacteria were washed three times with ice cold 1 x PBS. Bound phage were eluted with 0.2 M glycine buffer (pH 2.2) and titered on *E. coli* strain ER2738. Phage used for binding were 4-4-2 (expressing peptides having the sequence of TSITPWFFLSRP) (SEQ ID NO: 2) or OV1 (expressing peptides having the sequence TGRHTPWPHFMP) (SEQ ID NO: 4) which served as a negative control. p442 = competing peptide with sequence TSITPWFFLSRP (SEQ ID NO: 2); p442S = non-competing peptide with the sequence SLFWTTPIPSFR (SEQ ID NO: 5).

FIG. 6 shows the effect of buffer composition on phage binding to *F. tularensis* LVS (FT), *F. novicida* (FN) and *F. philomiragia* (FP). 10¹¹ bacteriophage were added to 10⁹ bacteria in 0.2 ml of the Tris-Mg buffer, 1X PBS and 0.1X PBS as indicated. After 1 hour at 4°C, the bacteria were washed 3 times with the same buffer used in the binding reaction (4°C). Bound bacteriophage were eluted with 0.2 M glycine (pH 2.2) and titered on *E. coli* strain ER2738. Phage used for binding were 4-4-2 (expressing peptides having the sequence of TSITPWFFLSRP) (SEQ ID NO: 2) or OV1 (expressing peptides having the sequence TGRHTPWPHFMP) (SEQ ID NO: 4) which served as a negative control.

FIG. 7 shows the effect of growth media on phage binding to *F. tularensis* LVS (FT), *F. novicida* (FN) and *F. philomiragia* (FP). Bacteria were grown in either trypticase soy (TSB) or Chamberlain minimal medium to mid-log phase. Bacteria were collected by centrifugation and resuspended in 1X PBS at a concentration of 5 x 10⁹ bacteria/ml. 10¹¹ bacteriophage were added to the bacteria in 0.2 ml of 1X PBS. After 1 hour at 4°C, the bacteria were washed 3 times with 1X PBS (4°C). Bound bacteriophage were eluted with 0.2 M glycine (pH 2.2) and titered on *E. coli* strain ER2738. Phage used for binding were 4-4-2 (expressing peptides having the sequence of TSITPWFFLSRP) (SEQ ID NO:

2) or OV1 (expressing peptides having the sequence TGRHTPWPHFMP) (SEQ ID NO: 4) which served as a negative control.

SUMMARY

Study of the biology and the mechanisms of pathogenicity of *Francisella* have been impaired by a lack of research and diagnostic tools. This lack of information has hampered the development of diagnostic assays and kits, as well as the identification of novel proteins and other targets for use in drug discovery programs and in vaccines. Therefore, one object of the present disclosure is to provide reagents that identify *Francisella* strains, such as, but not limited to, *F. tularensis* and *F. novicida*. In the furtherance of this object, in one embodiment peptide sequences are used as the reagents. It is a further object of the present disclosure to provide diagnostic assays using the reagents identified for the identification of *Francisella* strains, such as, but not limited to, *F. tularensis* and *F. novicida*. It is another object of the present disclosure to provide diagnostic assays suitable for the rapid detection of *Francisella* strains, such as, but not limited to, *F. tularensis* and *F. novicida*. Such rapid detection may prove useful, for example, in the event of an intentional or accidental release of *Francisella* strains. In addition it is an object of the disclosure to provide such reagents as research tools for the study and characterization of *Francisella* strains, such as, but not limited to, *F. tularensis* and *F. novicida*. Further, it is an object of the invention to use such reagents in order to provide vaccines useful for protection against *Francisella* strains, such as, but not limited to, *F. tularensis* and *F. novicida*.

DETAILED DESCRIPTION

F. tularensis is a tiny, non-motile, aerobic, gram-negative coccobacillus. It is a fastidious organism and usually requires cysteine supplementation for good growth on general laboratory media. *F. tularensis* has a thin capsule consisting of lipids, carbohydrates and proteins, all of which may contribute to the virulence (18). Biochemically, the organism is fairly inert, using glucose as the carbon source. It is a hardy non-spore forming microorganism, that is able to survive for weeks at low

temperatures in water, moist soil, hay and decaying animal carcasses (19). *F. tularensis* has been divided into two major biovars (20). *F. tularensis* biovar *tularensis* (type A) is the most common in the United States and is recovered from rodent and ticks and is highly virulent for rabbits and human. *F. tularensis* biovar *paleartica* (type B) is more common outside the United States and is recovered from water, mosquitoes, and aquatic mammals, and is relatively avirulent for rabbits and human. Both subspecies cannot be distinguished serologically although they may be differentiated by 16S RNA sequencing (21). Other *Francisella* strains include *F. philomiragia* (which shares a moderate 30-40% homology to *F. tularensis*) and *F. novicida* (which shares an approximate 90% homology to *F. tularensis*) (22).

Very little is known about the mechanisms of virulence of *Francisella*. This pathogen is capable of growing in macrophages from rodents including mice, rats and guinea-pigs as well as human monocytes (23, 24). *Francisella* appears to be able to inhibit phagosome-lysosome fusion (23). However, the intracellular compartment occupied by *Francisella* is acidified, an event thought to facilitate acquisition of iron, which is essential for growth (25). There is also evidence that *Francisella* can replicate in some types of phagocytic cells, such as, but not limited to, fibroblasts and hepatocytes (26, 27). Data from experimental animal infections suggest that *in vivo*, *F. tularensis* is rarely found extracellularly and replicates predominantly within the macrophage (24, 25).

Molecular mechanisms involved in the virulence and the intracellular growth of *Francisella* are not known. Two genes required for the intramacrophage growth of *Francisella novicida*, a closely related bacterium, have been reported (28), but their exact function remains to be identified. There have been a number of reports of components in the outer membrane and LPS and their potential role(s) in inducing an immune response (29-36), but the potential use of these components as therapeutic targets or as diagnostic reagents has not been described. At least one cell-surface polysaccharide antigen (O-antigen) has been isolated by acid hydrolysis of the bacterial lipopolysaccharide (37; 38); this antigen is related to antigens on other bacteria such as, but not limited to, *Pseudomonas aeruginosa* and *Shigella dysenteriae* and probably would not provide an appropriate target for therapeutic or diagnostic reagents. Further,

the O-antigen by itself appears not to confer immunity to systemic or aerosol challenge with *F. tularensis* (39).

In this disclosure, new methods for the identification and isolation of novel reagents capable of identifying, or aiding in the identification of, *Francisella* strains, such as, but not limited to, *F. tularensis* and *F. Novicida* disclosed. The reagents may be used in diagnostic assays and kits to diagnose the presence of *Francisella* strains. In addition the agents identified may be used as research tools for the study and characterization of *Francisella* strains. In one embodiment, the reagents identified are peptides. In one embodiment, the reagents identified may be used to identify molecular targets and these molecular targets may be used as antigens to provide vaccines useful for protection against *Francisella* strains, such as, but not limited to, *F. tularensis* LVS and *F. novicida*. One means for identifying such reagents is the technique of phage display. In one method of phage display, random peptide libraries are displayed on the surface of bacteriophage M13 (44-47). Such libraries have been used in a number of different applications, including epitope mapping (47-50), mapping protein-protein contacts (47), and identification of peptide mimics of non-peptide ligands (51-54). Phage display methods do not depend on the protein target being immunogenic, an advantage over the use of monoclonal antibodies for developing diagnostic reagents. Bioactive peptides can be selected either against immobilized purified targets (55) or against intact cells (56-59). One such library is the Ph.D.-12 library (New England Biolabs), in which 2.7×10^9 different random 12-amino-acid peptides have been fused to the amino terminus of the pIII protein, resulting in 3 to 5 copies of a random peptide sequence on the surface of each phage.

In the present disclosure, the standard phage display biopanning strategy has been modified to allow for selection of peptides that are capable of identifying *Francisella* strains. The *Francisella* strain to be identified can vary depending on the selection of organisms in the Negative/Positive selection strategy described herein. In one embodiment, the *Francisella* strain is selected from the group consisting of *F. tularensis* and *F. Novicida*, or sub-species thereof. This strategy has been termed "Negative/Positive" selection, because the first step in each round of selection is a

negative selection step, to remove phages that bind to related cell types or organisms. This negative selection is followed by a positive selection that favors binding to the target cell type or organism. A schematic of the steps involved in one embodiment of the Negative/Positive selection step is shown in FIG. 1. The details of the Negative
5 positive selection are discussed below.

In one embodiment, the Negative/Positive selection strategy illustrated in FIG. 1 was used to identify peptides that bind to *F. tularensis* LVS and not to *F. philomiragia*. In this embodiment, *F. philomiragia* is used in the negative selection step and is termed the surrogate strain and *F. tularensis* LVS is used in the positive selection step and is
10 termed the target strain. *F. tularensis* LVS and *F. philomiragia* share about 30-40% DNA homology (22). Therefore, some of the differences should represent differences in targets found on the cell surface. The Negative/Positive selection strategy could also detect differences in the amount of individual targets (such as, but not limited to, protein targets) on the surface of the surrogate and target strains, provided that this
15 target was in substantially higher abundance on the target strain than on the surrogate strain. It should be noted that organisms other than *F. tularensis* LVS and *F. philomiragia* can be used as the target and surrogate strains in the Negative/Positive biopanning procedure. For example, *F. tularensis* Shu-4 could be used in place of *F. tularensis* LVS and *F. novicida* could be used in place of *F. philomiragia*. These
20 substitutions are exemplary only and others may be used. In one embodiment the substituted *Francisella* strains are from the same biovar. In an alternate embodiment, the substituted *Francisella* strains are from a different biovar. In addition, more than one surrogate strain or target strain could be used. For example, both *F. novicida* and *F. philomiragia* could be used in the negative selection step. By altering the organisms
25 used in the negative selection steps, peptides specific for recognition of desired *Francisella* strains, such as, but not limited to, but not limited to, *F. tularensis* strains or *F. novicida* strains and/or peptides specific for only the human pathogenic forms of *Francisella* such as, but not limited to, but not limited to, *F. tularensis* Shu-4, can be identified. Such reagents can be used as important diagnostic tools. The availability of
30 any diagnostic tool for *Francisella* strain will also reduce the chances for confusion of tularemia infection with other diseases with similar symptoms (11, 63).

The percent homology between the *Francisella* strain used in the negative selection step (the surrogate strain) and the *Francisella* strain used in the positive selection step (the target strain) may impact the nature of the peptides identified that bind to the target *Francisella* strain. For example, if the surrogate strain shares a low
5 homology with the target strain, a wider variety of peptides will be identified. Conversely, if the surrogate strain shares a high homology to the target strain, a restricted set of peptides will be identified. The homology may be defined in terms of nucleic acid sequence. In one embodiment, the target strain shares 30-40% homology in its DNA chromosome to the surrogate strain. In an alternate embodiment, the target
10 strain shares 40%-75% homology in its DNA chromosome to the surrogate strain. In yet an alternate embodiment, the target strain shares a 75%-99% homology in its DNA chromosome to the surrogate strain. The percent homology of the target strain to the surrogate strain can be selected by one of skill in the art. Furthermore, the percent homology between the target and surrogate strains can be modulated to identify
15 peptides with desired characteristics.

In addition, the percent homology of the target strain to known human pathogenic forms of the *Francisella* strains can impact the peptides identified. The closer the homology between the target strain and the known human pathogenic forms of the *Francisella* strains, the more likely the peptides identified in the selection
20 strategy will react with pathogenic *Francisella* strains. In one embodiment, the target strain is related to human pathogenic *Francisella* strains such that the peptides identified with the target strain will react with a number of pathogenic *Francisella* strains. Such an increased capacity for recognizing numerous *Francisella* strains can be of value, especially if new pathogenic forms of *Francisella* are required to be detected,
25 as may be the case if *Francisella* were used as a biological weapon. This aspect is applicable to diagnostic testing and treatment, since the treatment for all *Francisella* infections is identical. In one embodiment, the target strain is selected with a percent homology to known human pathogenic *Francisella* strains, such as, but not limited to, *F. tularensis* Shu-4, such that the peptides binding the target strain will react with the
30 human pathogenic forms of *Francisella*. In one embodiment, the target strain shares 30-40% homology in its DNA chromosome to *F. tularensis* Shu-4. The percent

used as the target strains. This embodiment is exemplary only and serves to illustrate the operation of the methods disclosed, and can be altered as discussed above. *F. philomiragia* bacteria were grown in trypticase-soybean broth (supplemented with 0.1% cysteine) to approximately 10^9 (growing in mid-exponential phase). Bacteria were washed at least once with 1X PBS (4°C). 2×10^{11} phage particles were added to approximately 10^9 *F. philomiragia* bacteria in 4°C 1X PBS and allowed to bind for 1 hour at 4°C. In alternate embodiments, the binding step can occur at other temperatures, such as, but not limited to, 37°C. In these cases, the wash steps performed both before and after the binding step are performed at the temperature of the binding step. *Francisella* are resistant to cold, so the 4°C binding step does not affect their viability. After one hour incubation, *F. philomiragia* bacteria were collected by centrifugation and the supernatant added to approximately 10^9 *F. tularensis* LVS bacteria in 4°C 1X PBS. *F. tularensis* LVS bacteria were grown as described above for *F. philomiragia*, and prepared for phage binding as described above. After one hour incubation in 1X PBS at 4°C, *F. tularensis* LVS bacteria were washed three times with 1X PBS (4°C) and then bound phages eluted by treatment with low pH buffer (0.2 M glycine, pH 2.2, at the same temperature used for the binding steps) and neutralized with 1 M Tris/HCl, pH 9.1. This step partially inactivates the bacteria themselves. Any remaining viable *Francisella* bacteria are removed by filtration through a 0.22 micron filter (without detectable loss of phage). Eluted phages were amplified in 20 mL Luria-Bertani medium containing the *E. coli* ER2783 at 37°C (other appropriate *E. coli* strains may also be used). Phage from liquid cultures are obtained by clearing the supernatant twice by centrifugation at 12,000 g for 15 min (each at 4°C), and precipitating with 1/6 vol. of 20% poly(ethylene glycol)-8000/2.5 M NaCl at 4°C overnight. Phage pellets are resuspended in 1 ml NaCl/Tris (50 mM Tris/HCl, 150 mM NaCl), and precipitated with 20% poly(ethylene glycol)-8000/2.5 M NaCl for 1 hr. Amplified phage are resuspended in 200 ml NaCl/Tris, 0.02% NaN₃, and are used for the subsequent round of biopanning (if desired) to select appropriate peptides.

In the embodiment discussed above, three additional rounds of selection were completed to select for peptides that bound *F. tularensis* LVS preferentially as compared to *F. philomiragia*. Increasing the rounds of selection may decrease the

homology may be determined at the nucleic acid level. In an alternate embodiment, the target strain shares 40-75% homology in its DNA chromosome to *F. tularensis* Shu-4. In a yet another alternate embodiment, the target strain shares 75-95% homology in its DNA chromosome to *F. tularensis* Shu-4. The percent homology of the target strain to the human pathogenic forms of *F. tularensis* can be selected by one of skill in the art. Furthermore, the percent homology of the target strain to the human pathogenic forms of *F. tularensis* can be modulated to identify peptides with desired characteristics.

In an alternate embodiment, human pathogenic forms of *Francisella* are used as the target strain. If peptides with specificity for the Shu-4 strain can be identified, the peptides can be used to identify the cell-surface molecule on the pathogenic strains and to identify drug targets specific for the human pathogenic strains. In this embodiment, the peptides identified will bind to the strain of *Francisella* used as the target strain.

The affinity and/or avidity of the peptides selected may also be impacted. For example, if the surrogate strain shares low homology with the target strain, then the peptides selected may be of decreased affinity and/or avidity. The number of selection rounds may also impact the affinity and/or avidity of the peptides identified as discussed below.

In summary, by choosing the homology of the surrogate and target strains used in the negative and positive selection steps, the characteristics and specificity of the peptides identified can be modulated. Given the teachings of the present disclosure, one of ordinary skill in the art would be able to choose appropriate surrogate strains and target strains without undue experimentation.

As used in this disclosure, the term "percent homology" of two nucleic acid sequences is determined using the DNA:DNA hybridization method described in reference 22. Other methods of determining the percent homology may be used as is known in the art.

As discussed above, the 12 amino acid Ph.D.-12 Phage Display library was used in one embodiment of the Negative/Positive selection method described herein. Other phage display libraries or other peptide libraries could be used and should be considered within the scope of the present disclosure. In one embodiment of the method disclosed, *F. philomiragia* was used as the surrogate strain and *F. tularensis* LVS was

number of candidate phage peptide sequences for analysis and select and/or enrich for those phage having higher specificities and/or higher affinities for *F. tularensis* LVS binding. However, one round of selection may be sufficient. In other instances, additional rounds of selection may be used. One of ordinary skill in the art will be able to determine if additional rounds of selection are required to isolate reagents with desired characteristics. For example, if only reagents with the highest binding affinity are desired, multiple rounds of selection may yield superior results. After 4 rounds of selection using the biopanning strategy above, individual plaques were amplified and phage DNA purified for DNA sequencing, using a modified Sanger sequencing reaction and the sequencing primer: 5' GTATGGGATTTTGCTAAACAAC 3' (SEQ ID NO: 1). From the DNA sequence, the amino acid sequence of the peptide was determined. Two 12mer peptide sequences were isolated after 4 rounds of selection: TSITPWFFLSRP (SEQ ID NO: 2) (phage plaque 4-4-2: found in 4 out of 9 plaques sequenced) and LPISNPLPIKRS (SEQ ID NO: 3) (2 out of 9 plaques sequenced). After 7 rounds of selection, each of these phages were still present in the selected population.

The binding and elution conditions can be selected to favor the isolation of reagents (such as, but not limited to, peptides) with desired characteristics. These techniques are well known to those of ordinary skill in the art. As an example of such methods, to favor the isolation of phages that express sequences that bind tightly to the target strain, the incubation times for the binding and elution steps can be varied. In one embodiment, to favor the isolation of phages that express sequences that bind tightly to the target strain an initial short (5-10 minutes) elution with 0.2 M glycine (pH 2.2) is used, followed by a second longer elution with the same buffer. Phage that express sequences that do not bind tightly to the target strain will be eluted during the first elution, with phage that express sequence that bind tightly to the target strain being eluted during the second elution. In addition, the first elution could be performed with glycine buffer with a different pH. In one embodiment, the pH of the glycine buffer used in the first elution is pH 3.0 to 6.0. The above example is exemplary only and not meant to restrict other methodologies used to select phages expressing sequences with desired binding characteristics.

As an alternative to the use of phage display, single-chain antibody libraries (72) can be screened using the "Negative/Positive" selection strategy described. Selection could be done and the selected phage sequences analyzed using approaches like those described elsewhere in this disclosure. In addition, one of the Applicants has constructed a phage display single chain antibody library, taking advantage of the natural single chain antibodies found in camels and llamas. These libraries contain variable regions of 14-19 amino acids and are expressed on the surface of M13 bacteriophage grown in *E. coli*. The "Negative/Positive" selection strategy could be used for these selections as well.

The phage isolated carrying the TSITPWFFLSRP (SEQ ID NO: 2) 12 mer peptide showed preferential binding to *F. tularensis* LVS and *F. novicida* as compared to *F. philomiragia* (FIG. 2). 10¹¹ phages were added to cultures of 10⁹ *F. tularensis* LVS, *F. novicida*, or *F. philomiragia* cells (mid-log phase growth) in 1X PBS and incubated at 4°C or at 37°C for two hours. After incubation, the cells were washed three times with 1X PBS at room temperature. Bound bacteriophage were eluted with 0.2M glycine (pH 2.2) and dilutions were plated onto *E. coli* ER2783 cells as described. Phage titers were in the range of 1 x 10⁵ to 3 x 10⁸ plaques recovered. In FIG. 2, the ratio of binding of the phages to *F. tularensis* LVS and *F. novicida* to *F. philomiragia* were compared. At both binding temperatures, there was greater than a 100 fold binding of phage 4-4-2 expressing peptides having the sequence of SEQ ID NO: 2 to *F. tularensis* LVS and *F. novicida* as compared to *F. philomiragia*. As a negative control, a phage expressing the sequence TGRHTPWPHFMP (OV1) (SEQ ID NO: 4), which was obtained by selection on ovarian cancer cells was used. The same phage showed approximately equal binding to *F. novicida*, a more closely related *Francisella* strain to *F. tularensis*. Phage binding tests of the peptide expressing SEQ ID NO: 3 showed no specific binding to *F. tularensis* LVS compared to *F. philomiragia*.

SEQ ID NO: 2 was tested for binding to other bacteria that might be encountered in a clinical laboratory (FIG. 3). The binding of phage expressing peptides having the sequence of SEQ ID NO: 2 to gram-negative *E. coli* DH5α (a strain lacking sex pili and unable to grow M13 phage), gram positive *Staphylococcus aureus* (ATCC 6538), and gram positive *Enterococcus hirae* (ATCC 8043) bacteria were examined.

Phage binding experiments were performed as described above at 4° C and 37° C. All of these strains showed equivalent binding to phage expressing peptides having the sequence of SEQ ID NO: 2 (phage 4-4-2) and SEQ ID NO: 4 (OV1 negative control), all in the range of 10⁵-10⁶ phage recovered from one ml of bacteria in mid-log phase at an O.D.₆₀₀ of 1. This level of binding is similar to the level observed with gram-negative *F. philomiragia* and 20-100 fold lower than the level of phage binding we see to *F. novicida* and *F. tularensis* LVS. Similar results were also obtained using *Pseudomonas aeruginosa*. These results show that the biopanning strategy described can identify phages expressing peptide sequences that can identify *Francisella* strains, such as, but not limited to, *F. tularensis* LVS and *F. novicida* and related strains, in the presence of bacteria that are routinely encountered in the clinical laboratory setting.

In order to characterize the target to which the peptide of SEQ ID NO: 2 binds, the surface of *F. tularensis* LVS and of *F. philomiragia* was digested with trypsin for 1 hour at 4°C or at 37°C (FIG. 4). Soybean trypsin inhibitor (STI) was then added to inhibit the protease and the cells were washed with 1X PBS 3 times. Phage binding experiments were performed as described above. The 37°C experiment is shown in FIG. 4 and is typical of the results observed. For phage 4-4-2 expressing peptides having the sequence of SEQ ID NO: 2; there was a distinct trypsin sensitivity to binding to *F. tularensis* LVS, while there is a small but reproducible increase in binding by this phage to *F. philomiragia* under the same conditions. On both bacteria, the negative control phage expressing peptides having the sequence of SEQ ID NO: 4 showed substantially lower binding and an increase in binding after trypsin treatment, as if trypsin treatment reveals a target to which the phages can bind. As can be seen in FIG. 4 when compared to FIG. 2, after trypsin digestion the level of phage 4-4-2 (expressing SEQ ID NO: 2) binding to *F. tularensis* LVS is 10-20% that seen when no trypsin is used. This strongly suggests that the molecule to which SEQ ID NO: 2 binds is sensitive to trypsin digestion.

In order to verify that the binding observed was specific for the peptide shown in SEQ ID NO: 2, competition experiments were performed (FIG 5.). 1 x 10¹¹ phage expressing peptides having the sequence of SEQ ID NO: 2 (phage 4-4-2) or SEQ ID NO: 4 (OV1 negative control) were mixed with peptides p442 having the sequence of

SEQ ID NO: 2 (positive control competing peptide) or p442S having the sequence SLFWTTPIPSFR (SEQ ID NO: 5, scrambled negative control non-competing peptide having the same amino acid composition as the peptide shown in SEQ ID NO: 2). For p442, the peptide was used at concentrations of 0, 150 nM, 1.5 uM and 15 uM; for p442S, the peptide was used at concentrations of 0, 165 nM, 1.6 uM and 16.5 uM. The phage and peptide were added to 1×10^9 *F. tularensis* bacteria and allowed to bind for 1 hour at 4°C in 1x PBS. After binding, bacteria were washed three times with ice cold 1 x PBS. Bound phage were eluted with 0.2 M glycine buffer (pH 2.2) and titered on *E. coli* strain ER2738. As can be seen from FIG. 5, the addition of p442 having the sequence of SEQ ID NO: 2 decreased binding of phage 4-4-2 to *F. novicida* bacteria. The addition of p442S having the sequence of SEQ ID NO: 5 (negative control) did not inhibit the binding of phage 4-4-2. Similar results were obtained for *F. tularensis* LVS.

The buffers used in the binding and wash steps can also influence the binding characteristics of the reagents described in the present disclosure. The previous examples described above used 1X PBS as the binding buffer and in the various wash steps prior to phage elution. FIG. 6 shows the effects of Tris-Mg buffer, 1X PBS and 0.1X PBS on binding of phage expressing peptides having the sequence of SEQ ID NO: 2 (phage 4-4-2) or SEQ ID NO: 4 (OV1 negative control) to *F. tularensis* LVS, (FT), *F. novicida* (FN) and *F. philomiragia* (FP). 1×10^{11} phage were added to 1×10^9 bacterial cells as indicated in the various buffers shown. Phage were allowed to incubate for 1 hour at 4°C and were washed 3 times with the same buffer used for phage binding. Bound bacteriophage were eluted with 0.2 M glycine (pH 2.2) and titered on *E. coli* ER2738. The number of phage bound under each condition is shown in FIG. 6. As can be seen, the use of Tris-Mg buffer favored the binding of phage 4-4-2 to *F. tularensis* LVS cells over *F. novicida* and *F. philomiragia*. Using Tris-Mg buffer, phage 4-4-2 showed specificity for the identification of *F. tularensis* LVS. Binding of the OV1 phage to *F. novicida* and *F. philomiragia* was equal to or greater than the binding of phage 4-4-2 to these bacteria. The use of 1X PBS favored the binding of phage 4-4-2 to *F. novicida* over *F. tularensis* LVS and *F. philomiragia*. However, in 1X PBS buffer, phage 4-4-2 showed specificity for the identification of *F. tularensis* LVS and *F. novicida*. Binding of the OV1 phage to *F. philomiragia* was equal to the binding of

phage 4-4-2 for this bacterium. Of note, the number of phage 4-4-2 binding *F. tularensis* LVS bacteria was not decreased significantly in the 1X PBS buffer. However, the amount of phage 4-4-2 binding to *F. novicida* bacteria was increased. Neither phage expressing peptides having the sequence of SEQ ID NO: 2 (phage 4-4-2) or SEQ ID NO: 4 (OV1 negative control) bound the *Francisella* strains tested in 0.1X PBS. This data suggests that the components of the wash and binding buffers can influence the binding specificity and selectivity with which the peptide reagents interact with their cellular targets.

The composition of the growth media used to grow the *Francisella* strains may also influence the binding characteristics of the reagents identified in the present disclosure. FIG. 7 shows the effect of trypticase soy broth (TSB) and Chamberlain minimal media on phage binding. TSB is a richer growth medium than Chamberlain. *F. tularensis* LVS (FT), *F. novicida* (FN) and *F. philomiragia* (FP) bacteria were grown in either TSB or Chamberlain minimal medium to mid-log phase. Bacteria were collected by centrifugation and resuspended in 1X PBS at a concentration of 5×10^9 bacteria/ml. 10^{11} bacteriophage were added to the bacteria in 0.2 ml of 1X PBS at either 4°C or 37°C. After 1 hour at 4°C or 37°C, the bacteria were washed 3 times with 1X PBS (at the temperature used for binding). Bound bacteriophage were eluted with 0.2 M glycine (pH 2.2, at the temperature used for binding) and titered on *E. coli* strain ER2738. Phage used for binding were 4-4-2 (expressing peptides having the sequence of TSITPWFFLSRP) (SEQ ID NO: 2) or OV1 (expressing peptides having the sequence TGRHTPWPHFMP) (SEQ ID NO: 4) which served as a negative control. As can be seen in FIG. 7, the growth on TSB stimulated binding of phage 4-4-2 on *F. novicida* and *F. tularensis* LVS, although the stimulatory effect observed with *F. tularensis* LVS was not as great. This suggests that the target of the peptide expressed by the 4-4-2 phage can be increased by growth in rich media.

In order to optimize the Negative/Positive selection strategy employed in the present disclosure and to ensure the safety of the selection strategy, several assay parameters were evaluated. First, the sensitivity of *Francisella* strains and the phage to low pH was evaluated. The selection strategy uses a pH 2.2 wash to remove bound phage. After a 15 minute incubation of *F. tularensis* LVS or *F. philomiragia* at 4°C

with 0.2 M glycine/HCl buffer (pH 2.2), the bacteria were washed with trypticase soy broth supplemented with 0.1% cysteine (TS-C) and plated on cysteine-heart agar supplemented with 5% defibrinated horse blood (CHA-B) to assess colony formation. Treated *F. philomiragia* cells were unable to form colonies after incubation at low pH.

5 Treated *F. tularensis* LVS cells were partially inactivated by the acidic treatment (70% inactivation). This result provides a level of biosafety to the selection strategy, since the bacteria appear to be significantly inactivated by treatment at low pH. The effect of the low pH on phage titre was also examined. 1×10^6 phage were incubated with pH 2.2 glycine-HCl buffer for 0, 5, 10, and 20 minutes at 4°C and at 37°C. After incubation, 10 the phage solution was neutralized with 1 M Tris base, pH 9.1, and the phage titer determined. There was no significant decrease in the phage titer after even 20 minutes in acid indicating the phage was not adversely affected by the pH 2.2 wash.

It had been reported that heat inactivation of *Francisella* strains can be accomplished by incubation at 60°C for 10-20 minutes (61). There was a dramatic 15 decrease in viable *Francisella* bacteria recovered after heat treatment, with no viable colonies were recovered after 20 minutes at 60°C. In addition, incubation of M13 phages, such as, but not limited to, those found in the phage display library used in the current disclosure, at 60°C for 1 hour does not significantly reduce the phage titer. An alternative or additional means to inactivate *Francisella* strains is UV inactivation (70). 20 A UV dose of $<20 \text{ J/m}^2$ will reduce the viability of *F. novicida* by at least 5 logs within 20 minutes at room temperature.

Independently of the pH and heat inactivation of the bacteria, filtration through a 0.22µm filter was also shown to remove viable *Francisella* bacteria, as determined by plating filtered bacterial cultures on CHA-B plates and observing colony formation. As 25 a result, the bound bacteriophages can be recovered and the *Francisella* bacteria eliminated in two fast and simple steps.

Finally, the ability of the added phage to lyse the *Francisella* strains used was evaluated. Using a spot assay with dilutions of phage lysate (10^7 , 10^9 , 10^{11} phages per ml) on lawns of *F. tularensis* LVS and of *F. philomiragia*, it was determined that the 30 phages did not appear to lyse the *Francisella* strains used in the selection assay.

In the present disclosure, *Francisella* strains are grown on cysteine heart agar plates supplemented with 5% defibrinated horse blood (CHA-B) for 48 hours at 37°C, as previously described (69). For binding experiments, tryptic soybean broth supplemented with 0.1% cysteine (TS-C) was inoculated with one colony from a CHA-B plate and incubated overnight at 37°C. Inoculated broth culture will be incubated until the bacteria density reaches 10^8 to 10^9 CFU/ml. Stock of bacteria will be stored frozen at -70°C after addition of 10% glycerol.

All references cited herein are incorporated by reference to the extent allowed. The references discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior disclosure. The following claim is appended for the purpose of foreign priority only.

PROPHETIC EXAMPLES

Evaluation of Binding Specificity

In order to more carefully evaluate the binding specificity of the peptides identified, fusion proteins could be constructed by incorporating one copy of the identified peptide. In the Negative/Positive selection steps discussed above, the phage expressing the peptides express 3-5 copies of each peptide. In many cases, it is desirable to characterize the binding further in a situation where only one copy of the peptide is present. For such studies, one copy of the identified peptide sequences to be tested are fused to the C-terminus of either enhanced green fluorescent protein (EGFP) or to the amino terminus of β -galactosidase or other marker protein (such as, but not limited to, but not limited to green fluorescent protein, horseradish peroxidase and other marker proteins commonly used in the art). Such constructs will allow a more carefully measurement of binding specificity; to show that binding is peptide-specific, to determine the number of binding sites, and to measure the binding constant. By using fusion proteins to the N- terminus (β -galactosidase) or C-terminus (EGFP), the importance of having a free N- or C-terminus for binding specificity or avidity can be determined.

In one embodiment, candidate peptide sequences identified by the selection strategy above will be fused to the C-terminus of EGFP. Fusion proteins will be constructed to incorporate histidine or other appropriate affinity tags for easy purification of the fusion proteins. PCR may be used to add the identified peptide sequences onto the EGFP gene in an expression plasmid. As one negative control, a histidine-tagged EGFP construct will be included. As a second set of negative controls, EGFP fusions with the same amino acid composition as the identified peptides but with the amino acids in a different random order (generated using the Genetics Computer Group program SHUFFLE) will be generated (the peptide shown in SEQ ID NO: 5 was generated using this technique). Once amplified by PCR, the DNA product will be digested with restriction endonucleases for cloning into an expression vector. In one embodiment, BglIII and HindIII restriction endonucleases for cloning into the pET32a vector (Novagen) are used. Individual clones will be characterized from miniprep DNA (Qiagen) and the DNA sequence determined using the T7-reverse sequencing primer to sequence across the end of the pET32a vector. Correct clones will be transformed into an appropriate host, such as, but not limited to, *E. coli* BL21(DE3) cells, for expression of protein. Protein will be purified by standard methods, such as, but not limited to, by affinity purification on nickel affinity columns (Qiagen).

The purified proteins will be incubated with *F. tularensis* LVS or other appropriate *Francisella* strains to test for binding. Varying amounts of purified EGFP-peptide protein will be mixed in MH broth. After binding for 15 minutes at room temperature, at 37°C, or at 4°C, the bacteria will be washed three times with PBS (pH 7.2) or with MH broth. Binding will be assessed by the relative amount of fluorescent material visible during observation of the bacteria in a fluorescent microscope.

As an alternative, the peptide sequences can be fused to the amino terminus of β -galactosidase and X-gal used as a reagent to detect activity of the bound enzyme, by looking for the conversion of X-gal from a clear solution to a blue color. Using enzymatic methods for detection, the signal can be amplified by modulating the time for development. The fusion proteins would be constructed with histidine or other appropriate affinity tags, to allow easy purification of the fusion protein as discussed above. If necessary, any bound fusion protein can be stripped with mild acid (as done

for the selection assays) or whole cells with fusion protein still bound could be used. In these experiments, an X-gal solution is incubated with the protein or cells and the OD₄₂₀ determined. The experiment will be conducted so that the reaction is in the linear range with appropriate standard curves with which to compare the observed β -galactosidase activity. Controls would include β -galactosidase fusions with peptides for scrambled sequences and β -galactosidase protein alone as discussed above.

To demonstrate binding specificity of the identified peptide, competition experiments with a competing peptide will be performed. Competing peptide would be the same sequence as the peptide attached to EGFP or β -galactosidase. For immunofluorescence experiments, varying amounts of the competing peptide would be added with known amounts of the purified EGFP/ β -galactosidase-peptide fusion protein immediately prior to addition to the cells. Negative controls would be no peptide added or the scrambled peptide sequence (same amino acid composition but in a different sequence, as described above).

The binding affinity and the numbers of binding sites for the identified peptides can be determined by Scatchard Analysis as is standard in the art. In one embodiment, purified proteins will be labeled with ¹²⁵I to a specific activity of 1-2 μ Ci/ μ g, with CPM/ μ g determined by counting in a gamma counter and by Bradford assay. In one embodiment, the marker protein is EGFP. In this embodiment, labeled EGFP, labeled EGFP-peptide fusion proteins and labeled EGFP-scrambled peptide fusion proteins are prepared. Other marker proteins may be used, such as, but not limited to, but not limited to green fluorescent protein, horseradish peroxidase and other marker proteins commonly used in the art. The CPM/ μ g of protein will be obtained for each ¹²⁵I-labeled protein. *F. tularensis* LVS and *F. philomiragia* cells, or other appropriate *Francisella* strains, at a known density (such as, but not limited to, 10⁸/ml) will be incubated with known amounts of labeled protein at 4°C and at 37°C for one hour in PBS. After binding, the bacteria will be washed with PBS and the bound and free cpm determined by counting in a gamma counter. The binding affinities and the number of binding sites will be determined using Scatchard analysis.

In addition to the above, the purified fusion proteins (EGFP, EGFP-peptide fusion proteins and EGFP-scrambled peptide fusion proteins, or their β -galactosidase

counterparts) will be tested with a broad range of gram positive and gram negative bacteria to further characterize binding specificity. Examples of bacteria suitable for such use include, but are not limited to: *Bacillus subtilis*, *Bacillus anthracis*, *Listeria monocytogenes*, *Staphylococcus aureus*, *Streptococcus pyogenes*, *Enterococcus hirue*,
5 *Escherichia coli*, *Legionella pneumophila* and *Yersinia enterocolitica*. Cultures of each of these bacteria will be incubated with varying amounts of the EGFP- or β -galactosidase-peptide fusion proteins to assess the relative binding of protein by fluorescence or by conversion of X-gal to a blue color as discussed above.

Determination of Residues Critical for Binding

10 As part of the process to characterize peptide binding, the amino acid determinants within the peptide sequence that are important for binding will be determined, using a selection method described by Sidhu and co-workers (71). In this method alanine residues are substituted at each position in a known peptide binding sequence. By careful analysis of the genetic code, this strategy can allow substitution
15 of alanine at any position within the sequence (see Table 1, adapted from reference 71). After preparing this library of alanine substituted phages with a candidate peptide sequence, a positive selection experiment will be performed using a suitable *Francisella* strain (such as, but not limited to, *F. tularensis* LVS) and bound phages recovered. The bound phage will be recovered and a representative
20 number of phages will be sequenced. The frequency with which alanine residues appear at each position within the peptide sequence will be determined. Amino acids positions with a high frequency of alanine residues indicate positions not important in determining binding specificity. Positions allowing no alanine substitutions are essential to binding. In this manner, the critical amino acid residues responsible for
25 binding can be determined.

It is possible to improve the binding characteristics, such as, but not limited to, but not limited to, specificity and avidity, of the identified peptides using targeted selection approaches. After identification of the amino acid positions of the peptide that are not important to binding, an additional library of phages can be constructed in
30 which amino acids at the invariant amino acid positions are retained but in which the amino acids at the variable amino acid positions are substituted with all possible amino

acids. As an alternative means to improve binding specificity and/or avidity, a new random peptide sequence library can be constructed by incorporating random amino acid sequences on or both sides of the identified peptide sequence. The number of residues added is variable and may be as few as one residue or as many as 12. With these additional peptide libraries, additional "Negative/Positive" selection as described above can be performed to identify additional peptide sequences. Additional peptide sequences can be further characterized as described above. In this manner, the specificity and/or avidity of identified peptide sequence can be modulated.

Determining the Molecule(s) to Which the Identified Peptides Bind

In addition to use as diagnostic tools, the peptide reagents identified using the Negative/Positive selection strategy discussed can be used as research tools. The identity of the molecules bound by each identified peptide can be determined. The target of the identified peptides may be either a protein or other cell surface molecules, such as, but not limited to, a complex carbohydrates or lipopolysaccharides. The presence of a protein component as involved in peptide binding can be determined by trypsin digestion, or digestion with other appropriate enzymes. Using the identified peptides, it will be possible to determine what molecules are present on the target *Francisella* strain (for example *F. tularensis* LVS) that are not present on the *Francisella* strain used in the negative selection step. Using this approach, it will be possible to identify proteins that may be involved in the pathogenesis of *Francisella* strains. These cell-surface molecules might also provide research tools and specific drug targets that could be useful candidates for new therapeutics and for vaccine development. Additionally, these cell surface markers could provide new and more rapid diagnostics for tularemia.

To characterize cell surface molecules, fusion proteins expressing the identified peptide sequences or the shuffled version of the peptide sequences will be constructed. In one embodiment GST fusion proteins are used although other fusion proteins may also be employed as is known in the art. The PCR strategy to be used will be similar to that described for EGFP and β -galactosidase fusion proteins above. Proteins will be expressed in a suitable host, such as, but not limited to, *E. coli* BL21(DE3), and purified. If GST fusion proteins are used a Glutathione Sepharose 4B column

(Amersham Pharmacia Biotech) can be used for purification. The same column can be used for affinity purification of the cell surface molecules, from whole cell extracts of the appropriate *Francisella* strain. Alternatively, the identified peptide sequences or the shuffled version of the peptide sequences can be synthesized with an N- or a C-terminal cysteine, to allow direct coupling to an affinity matrix for subsequent purification.

If the target molecule bound by the identified peptide is a protein, the target will be purified by affinity chromatography to purify it sufficiently to submit for analysis and sequencing by mass spectrometry, or other appropriate means. If the molecule is a complex carbohydrate or lipopolysaccharide, appropriate analysis of complex carbohydrates and polysaccharides will be performed.

Preparation of cell extracts

The target molecules to which the identified peptides bind are expected to reside on the cell surface. Whether the target molecule is a protein, LPS, complex carbohydrate or other molecule, inactivated cell extracts (prepared as described above) can be used to purify the target molecule. Cell extracts are prepared from a suitable *Francisella* strain. In one embodiment *F. novicida* is used. Because the amount of specific binding is high on *F. novicida* and because of the potential to perform insertional mutagenesis in this organism (69) which we will use to confirm the identity of the cell-surface molecule to which phage 4-4-2 binds, we will start purification with this organism.

Analysis of Target Molecules

To determine if the target molecule contains LPS, the methods described by Dreisbach et al (34) will be used. Appropriate *Francisella* cultures are collected by centrifugation, extracted with methanol and acetone, lyophilized, and then extracted with hot phenol. After treatment with DNase and RNase, the LPS will be analyzed for binding by the identified peptides.

To determine if the target molecule is an outer membrane protein, the methods described by Fulop et al (33) will be used. Sonication will be used to disrupt the cells and sodium N-lauroyl sarcosinate will be used to solubilize the outer membrane proteins. SDS-PAGE can be used to analyze the proteins present in this preparation. The outer membrane proteins will be analyzed for binding by the identified peptides.

Several methods may be used to analyze binding of the identified peptide to isolated proteins. The identified peptides may be labeled with ^{125}I , at a tyrosine residue incorporated at the end of the synthesized peptides. The purified cell protein fractions may be purified by size by SDS-PAGE, blotted with nitrocellulose or other membrane, and probed with the radioactive peptides to identify fractions containing binding activity. Alternatively, the EGFP-peptide fusions discussed above may be used to perform co-immunoprecipitation experiments to purify the bound complex in conjunction with anti-GFP antibodies. If the binding constant is not strong, it may be necessary to cross-link the proteins with the bound fusion protein complex prior to immunoprecipitation. As controls, the negative control EGFP alone and/or EGFP-scrambled peptide fusion proteins could be used. Alternatively, appropriate synthetic peptides corresponding to the peptide sequence of the fusion protein could be added to the co-immunoprecipitation reaction to reduce the amount of complex recovered in a competition experiment.

The identification of the proteins identified can be carried out by a number of methods well known in the art. One embodiment of an identification method is mass spectroscopy to determine amino acid sequence, followed by analysis of proteomics databases. The protein complexes may be purified by affinity chromatography or co-immunoprecipitation as discussed above. In addition, peptides extracted from 2D gels and other gels can also be analyzed. Briefly, proteins in gel pieces are hydrolyzed *in situ* with trypsin and the resulting peptides analyzed by matrix assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS). The parent proteins are identified by submitting the profile of molecular weights of the tryptic peptides for statistical analysis using the MASCOT program at the matrixscience.com website. Confirmation of a protein's identity is carried out of the Qtof2 using MS-MS analysis. If the cell surface molecule is a protein, the protein can be identified once a mass for the protein is determined. A proteomics database containing the *F. tularensis* Schu-4 genome sequence is available and can be used to predict the masses of all predicted peptides in that genome.

Some of the identified peptides might recognize carbohydrate epitopes on the surface of *F. tularensis* LVS. LPS will be isolated from acetone-dried cells by the

procedure described by Dreisbach (34) or by Vinogradov *et al.* (37) which involves hot phenol extraction and precipitation of proteins and nucleic acids with TCA. O-specific polysaccharide will be cleaved off the LPS by heating it in 1% acetic acid for 2.5 hr. The O- polysaccharide will then be isolated by means of gel filtration chromatography on
5 Sephadex G-50. If peptides are found to bind to the O-specific polysaccharide, then its monosaccharide composition and structure will be further studied. Structural characterization of the O-antigen of *F. tularensis* strain 15 revealed that it consisted of a tetrasaccharide repeating unit containing the uncommon amino sugars, N-acetylquinosamine, N-formylquinosamine, and N-acetylgalacturonamide (37). These
10 amino sugars formed glycosidic bonds that were resistant to the usual acid hydrolysis conditions. Despite the inability to obtain free monosaccharides upon acid hydrolysis, Vinogradov *et al.* (37) was able to show that strain 15 O-antigen contained a tetrasaccharide repeating unit using ^1H and ^{13}C NMR procedures. Similar approaches will be used as in the analysis of O-antigen

15 A genetic approach may be used to confirm the identity of the cell surface marker molecule that is specifically bound by identified peptides. Based on the protein sequence obtained from the biochemical purification experiments described above, the corresponding genes will be knocked-out, and the loss of the cell surface marker on mutated bacteria will be confirmed by the absence of binding by specific peptides to *F.*
20 *novicida* or other *Francisella* strain. This approach will be used when the marker has been identified as a protein and is likely to be encoded by a single gene.

The main problem with performing knock-out experiments in *F. tularensis* LVS is that no system to generate allelic replacement mutants have been described for this microorganism. However, *F. tularensis* may be used if desired. Allelic replacement has
25 been successfully achieved in *F. novicida* which is very closely related to *F. tularensis* (69, 70). *F. tularensis* and *F. novicida* are virtually identical by 16S rDNA sequencing and by DNA hybridization and, although less virulent, *F. novicida* is still able to cause a tularemia-like illness in humans in rare cases (21, 22). Based on these observations, it has been suggested to consider *F. novicida* as a subspecies of *F. tularensis*. In addition,
30 as shown in FIG. 2, *F. novicida* was shown to strongly bind phage expressing SEQ ID

NO: 2. Therefore, *F. novicida* is a legitimate surrogate for *F. tularensis* in our knock-out experiments.

Briefly, the presence of a target molecule identified by a peptide as described in this disclosure will be confirmed in *F. novicida* by Southern blot analysis. DNA probes will be identified based on the known sequence from *F. tularensis* Schu-4 or by creating DNA probes specific for the amino acid sequences of the purified protein product encoded by this gene. Once identified, the gene will be then isolated from *F. novicida* genomic DNA and cloned into an appropriate vector, such as, but not limited to, pBlueScript KMI. Either a PCR amplification strategy (if the homology between *F. novicida* and *F. tularensis* Schu4 is high in this region) or a shotgun cloning strategy followed by identification of desired clone with DNA probes) can be used for this purpose. The resulting construct will then be subjected to *in vitro* transposon mutagenesis, using the EZ::TN<R6K_{Yori}/KAN-2> Insertion kit from Epicentre Technologies (Madison, WI). This kit can be used to randomly insert the <R6K_{Yori}/KAN-2> transposon into target gene cloned into the plasmid DNA *in vitro*, using kanamycin as a resistance selection marker. An aliquot of the insertion reaction will then be transformed in *E. coli* and transformed cells will be plated on LB plates containing 50µg/ml kanamycin. Transposon insertion clones can be sequenced from each end of the insert using forward and reverse transposon-specific primers, and only the clones carrying an insertion within the gene of interest will be selected.

The knock-out experiment will be performed as previously described (69). This approach is based on the fact that it is possible to transform *F. novicida* with plasmids exhibiting narrow host range (i.e., unable to replicate in *F. novicida*) carrying *Francisella* chromosomal DNA fragments and a kanamycin resistance marker (28, 69, 70). This observation has been exploited to generate knock-out mutants by homologous recombination in *F. novicida*. Constructs carrying the gene of interest interrupted by EZ::TN transposon will be introduced into *F. novicida* by chemical transformation as previously described (70) and cells will be plated onto CHA-B plates containing kanamycin. Kanamycin-resistant transformants will be isolated after 24 to 48h incubation at 37°C. Allelic exchange between the wild-type gene and the mutated gene

will be confirmed by Southern blot analysis of chromosomal DNA from each kan^r recombinant, using either the cloned gene itself or the EZ::TN transposon as a probe.

Mutants inactivated for a particular cell surface marker will then be tested for their binding of the corresponding peptide as described above. For example, in the case
5 of phage 4-4-2, we expect absence of specific binding by the phage as a consequence of the loss of the marker. The binding potential of mutant *F. novicida* knock-outs can be determined as described above.

REFERENCES

1. **Fauci AS (2002).** NIAID Strategic Plan for Biodefense Research.
<http://www.niaid.nih.gov/dmid/pdf/strategic.pdf>.
2. **Christopher GW, Cieslak TJ, Pavlin JA and Eitzen EM.** 1997. Biological warfare: a historical perspective. *JAMA*. **278**: 412-417.
3. **Alibek K.** 1999, *In Biohazard*, New York NY: Random House, pp. 29-38.
4. **Saslaw S, Eigelsbach HT, Prior JA, Wilson HE and Carhart S.** 1961. Tularemia vaccine study, II: Respiratory challenge. *Arch. Intern. Med.* **107**: 134-146.
5. **Health Aspects of Chemical and Biological Weapons.** 1970. Geneva, Switzerland: World Health Organization; pp. 105-107.
6. **Kaufmann AF, Meltzer MI and Schmid GP.** 1997. The economic impact of a bioterrorist attack: are prevention and post-attack intervention programs justifiable? *Emerg. Infect. Dis.* **2**: 83-94.
7. **Ellis J, Oyston, PCF, Green M, and Titball RW (2002).** Tularemia. *Clin. Microbiol. Rev.* **15**: 631-646.
8. **Evans ME, Gregory DW, Schaffner W and McGee ZA.** 1985. Tularemia: A 30-year experience with 88 cases. *Medicine.* **64**: 251-269.
9. **Brooks GF and Buchanan TM.** 1970. Tularemia in the United States: Epidemiologic aspects in the 1960's and follow-up of the outbreak of tularemia in Vermont. *J. Infect. Dis.* **121**: 357-359.
10. **Olsen PF.** 1975. *In* Hubbert WT, McCulloch WF, Schnurrenberger PR, eds. *Diseases Transmitted From Animals to Man*. Springfield, Ill: Charles C Thomas: 191-222.
11. **Quan SF, McManus AG and von Fintel H.** 1956. Infectivity of tularemia applied to intact skin and ingestion in drinking water. *Science.* **123**: 942-943.
12. **Foshay L.** 1940. Tularemia: A summary of certain aspects of the disease including methods for early diagnosis and the results of serum treatment in 600 patients. *Medicine.* **19**: 1-83.
13. **Pullen RL and Stuart BM.** 1945. Tularemia: Analysis of 225 cases. *JAMA.* **129**: 495-500.

14. Tigertt WD. 1962. Soviet viable *Pasteurella tularensis* vaccines: A review of selected articles. *Bacteriol. Rev.* 26: 354-373.
15. Eigelsbach HT and Downs CM. 1961. Prophylactic effectiveness of live and killed tularemia vaccines, I: Production of vaccine and evaluation in the white mouse and guinea pig. *J. Immunol.* 87: 415-425.
16. Hornick RB and Eigelsbach HT. 1966. Aerogenic immunization of man with live tularemia vaccine. *Bacteriol. Rev.* 30: 532-538.
17. Conlan JW, KuoLee R, Shen H, and Webb A (2002). Different host defences are required to protect mice from primary systemic vs pulmonary infection with the facultative intracellular bacterial pathogen, *Francisella tularensis* LVS. *Microbial Pathogenesis* 32: 127-134.
18. Pavlova IB, Meshcheryakova IS and Emelyanova OS. 1967. Study of the microstructure of the two races of the tularemia bacterium in strains with different degrees of virulence. *J. Hyg. Epidemiol. Microbiol. Immunol.* 11: 320-327.
19. Hopla CE. 1974. The ecology of tularemia. *Adv. Vet. Sci. Comp. Med.* 18: 25-53.
20. Eigelsbach HT and McGann VG. 1986. Gram-negative aerobic rods and cocci. Genus *Francisella* Dorofe'ev 1947, 176^{AL}. In: Krieg NR, Hold JG, eds. Vol 1. *Bergey's Manual of Systematic Bacteriology*. Baltimore, Md: Wilkins & Wilkins; 394-399.
21. Forsman M, Sandström G and Jaurin B. 1990. Identification of *Francisella* species and discrimination of type A and type B strains of *F. tularensis* by 16S rRNA analysis. *Appl. Environmental Microbiol.* 56: 949-955.
22. Hollis DG, Weaver, RE, Steigerwalt AG, Wenger JD, Most CW, and Brenner DJ (1989). *Francisella philomiragia* comb. Nov. (formerly *Yersinia philomiragia*) and *Francisella tularensis* Biogroup Novicida (formerly *Francisella novicida*) associated with human disease. *J. Clin. Microbiol.* 27:1601-1608.
23. Anthony LSD, Burke RD and Nano FE. 1991. Growth of *Francisella* spp. in rodent macrophages. *Infect. Immun.* 59: 3291-3296.
24. Fortier AH, Green SJ, Polsinelli T, Jones TR, Crawford RM, Leiby DA *et al.* 1994. Life and death of an intracellular pathogen: *Francisella tularensis* and the

macrophage. In *Macrophage-Pathogen Interactions*. Zwilling BS and Eisenstein TK eds. New York:Marcel Dekker, pp. 349-361.

25. Fortier AH, Leiby DA, Narayanan RB, Asafodjei E, Crawford RM, Nacy CA and Meltzer MS. 1995. Growth of *Francisella tularensis* LVS in macrophages: the
5 acidic intracellular compartment provides essential iron required for growth. *Infect. Immun.* 63: 1478-1483.

26. Tärnvik A. 1989. Nature of protective immunity to *Francisella tularensis*. *Rev. Infect. Dis.* 11: 440-451.

27. Conlan JW and North RJ. 1992. Early pathogenesis of infection in the liver with
10 the facultative intracellular bacteria *Listeria monocytogenes*, *Francisella tularensis*, and *Salmonella typhimurium*. *Infect. Immun.* 60: 5164-5171.

28. Baron GS and Nano FE. 1998. *MglA* and *MglB* are required for the intramacrophage growth of *Francisella novicida*. *Mol. Microbiol.* 29: 247-259.

29. Holm SE, Tärnvik A, and Sandstrom G (1980). Antigenic composition of a
15 vaccine strain of *Francisella tularensis*. *Int. Arch. Allergy Appl. Immunol.* 61:136-144.

30. Stulik J, Cerna J, Kovarova H, and Macela A (1989). Protein heterogeneity of *Francisella tularensis*: detection of proteins with antigenic determinants. *Folia Microbiologica* 34:316-323.

20 31. Sjöstedt A, Sandstrom G, Tärnvik A, and Jaurin B (1990). Nucleotide sequence and T cell epitopes of a membrane protein of *Francisella tularensis*. *J. Immunol.* 145:311-317.

32. Sjöstedt A, Sandstrom G, and Tärnvik A (1990). Several membrane polypeptides of the live vaccine strain *Francisella tularensis* LVS stimulate T cells
25 from naturally infected individuals. *J. Clin. Microbiol.* 28:43-48.

33. Fulop M, Manchee R, and Titball R (1996). Role of two outer membrane antigens in the induction of protective immunity against *Francisella tularensis* strains of different virulence. *FEMS Immunol. Med Microbiol* 13:245-247.

34. Khlebnikov VS, Golovliov IR, Kulevatsky DP, Tokhtamysehva NV, Averin SF, Zhemchugov VE, Pchelintsev SY, Afanasiev SS, and Shcherbakov GY (1996).

Outer membranes of a lipopolysaccharide-protein complex (LPS-17 kDa protein) as chemical tularemia vaccines. *FEMS Immunol. Med. Microbiol.* 13:227-233.

35. Dreisbach VC, Cowley S, and Elkins KL (2000). Purified lipopolysaccharide from *Francisella tularensis* live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon. *Inf. Immun.* 68:1988-1996.

36. Fulop M, Mastroeni P, Green M, and Titball RW (2001). Role of antibody to lipopolysaccharide in protection against low and high-virulence strains of *Francisella tularensis*. *Vaccine* 19:4465-4472.

37. Vinogradov EV, Shashkov AS, Knirel YA, Kochetkov NK, Tochtamysheva NV, Averin SF, Goncharova OV, and Khlebnikov VS (1991). Structure of the O-antigen of *Francisella tularensis* strain 15. *Carbohydr. Res.* 214: 289-297.

38. Vinogradov E, Perry MB, and Conlan JW (2002). Structural analysis of *Francisella tularensis* lipopolysaccharide. *Eur. J. Biochem.* 269: 6112-6118.

39. Conlan JW, Vinogradov E, Monteirol, MA, and Perry MB (2002). Mice internally-inoculated with intact lipopolysaccharide but not lipid A of O-chain from *Francisella tularensis* LVS rapidly acquire enhanced resistance against systemic and aerogenic challenge with the pathogen. *Microbial Pathogenesis*, in press.

40. Prior RG, Klasson L, Larsson P, Williams K, Lindler L *et al.* 2001. Preliminary analysis and annotation of the partial genome sequence of *Francisella tularensis* strain Schu 4. *J. Appl. Microbiol.* 91: 614-620.

41. Dennis D, Inglesby T, Henderson D, Bartlett J, Ascher M, Eitzen E, Fine A, Friedlander A, Hauer J, Layton M, Lillibridge, SF, McDade, JE, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, and Tonat K (2001).

Tularemia as a biological weapon. *JAMA* 285:2763-2773.

42. Gilligan PH (2002). Therapeutic challenges posed by bacterial bioterrorism threats. *Curr. Opin. Microbiol.* 5:489-495.

43. Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, Pavlin JA, Christopher GW, and Eitzen EM, Jr. (1997). Clinical recognition and management of patients exposed to biological warfare agents. *JAMA* 278:399-411.

44. **Grunow R, Spletstoeser W, McDonald S, Otterbein C, O'Brien T, Morgan C, Aldrich J, Hofer E, Finke E-J, and Meyer H. (2000).** Detection of *Francisella tularensis* in biological specimens using a capture enzyme-linked immunosorbent assay, an immunochematographic handheld assay and a PCR. Clin. Diagnos. Lab. Immunol. 7:86-90.
45. **Parmley SF and Smith GP (1988).** Antibody-selectable filamentous fd phage vectors; affinity purification of target genes. Gene 73:305-318.
46. **Cortese R, Monaci P, Nicosia A, Luzzago A, Felici F, Galfre G, Pessi A, Tramontano A, Sollazzo M (1995).** Identification of biologically active peptides using random libraries displayed on phage. Curr. Opin. Biotechnol. 6:73-80.
47. **Scott JK and Smith GP (1990).** Searching for peptide ligands with an epitope library. Science 249:386-390.
48. **Cwirla SE, Peteres EA, Barrett RW and Dower WJ (1990).** Peptides on phage: a vast library of peptides for identifying ligands. Proc. Natl. Acad. Sci. USA 87:6378-6382.
49. **Felici F, Castagnoli L, Musacchio A, Jappelli R, and Cesarini G (1991).** Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J. Mol. Biol. 222:301-310.
50. **Hong SS and Boulanger P (1995).** Protein ligands of the human adenovirus type 2 outer capsid identified by biopanning of a phage-displayed peptide library on separate domains of wild-type and mutant penton capsomers. EMBO J. 14:4714-4727.
51. **Devlin JJ, Panganiban LC and Devlin, PE (1990).** Random peptide libraries: a source of specific protein binding molecules. Science 249:404-406.
52. **Oldenburg KR, Loganathan D, Goldstein IJ, Schultz PG and Gallop MA (1992).** Peptide ligands for a sugar-binding protein isolated from a random peptide library. Proc. Natl. Acad. Sci. USA 89:5393-5397.
53. **Scott JK, Loganathan D, Easley RB, Gong, X and Goldstein IJ (1992).** A family of concanavalin A-binding peptides from a hexapeptide epitope library. Proc. Natl. Acad. Sci. USA 89:5398-5402.

54. **Hoess R, Brinkmann U, Handel T, and Pastan I (1993).** Identification of a peptide which binds to the carbohydrate-specific monoclonal antibody B3. *Gene* 128:43-49.
55. **O'Neil KT, Hoess RH, Jackson SA, Ramachandran NS, Mousa SA, and DeGrado WF (1992).** Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library. *Proteins* 14:509-515.
56. **Doorbar J and Winter G. (1994).** Isolation of a peptide antagonist to the thrombin receptor using phage display. *J. Mol. Biol.* 244:361-369.
57. **Goodson RJ, Doyle MV, Kaufman SE, and Rosenberg S (1994).** High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. *Proc. Natl. Acad. Sci. USA* 91:7129-7133.
58. **Barry MA, Dower WJ, and Johnston SA (1996).** Toward cell-targeting gene therapy vectors: selection of cell-binding peptides from random peptide-presenting phage libraries. *Nature Medicine* 2:299-305.
59. **Lee JH, Engler JA, Collawn JF, Moore BA (2001).** Receptor mediated uptake of peptides that bind the human transferrin receptor. *Eur. J. Biochem* 268:2004-2012.
60. **Cozens AL, Yezzi MJ, Kunzelmann K, Ohrui T, Chin L, Eng K, Finkbeiner WE, Widdicombe JH, Gruenert DC. 1994.** CFTR expression and chloride secretion in polarized immortal human bronchial epithelial cells. *Am. J. Respir. Cell Mol. Biol.* 10:38-47.
61. **Collins FM (2002).** "Pasteurella, Yersinia, and Francisella" web site <http://gsbs.utmb.edu/microbook/ch029.htm>
62. **Overholt EL, Tigertt WD, Kadull PJ et al. 1961.** An analysis of forty-two cases of laboratory acquired tularemia: Treatment with broad-spectrum antibiotics. *Am. J. Med.* 30: 785-806.
63. **Westerman EL and McDonald J. 1983.** Tularemia pneumonia mimicking Legionnaire's disease: Isolation of organisms on CYE agar and successful treatment with erythromycin. *South. Med. J.* 76: 1169-1171

64. **Syrjälä H, Schildt R and Raisanen S. (1991).** In vitro susceptibility of *Francisella tularensis* to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin. *Eur. J. Clin. Microbiol. Infect. Dis.* **10**: 68-70.
65. **Stelchen C, Chen P, Kearney JF, and Turnbough, CL Jr. (2002).**
 5 Identification of the immunodominant and other proteins of the *Bacillus anthracis* exosporium. *J. Bacteriol.*, in press.
66. **Knurr J, Benedict O, Heslop J, Vinson RB, McAndrew J, Kearney JF, and Turnbough CL Jr. (2002).** Peptide ligands that bind selectively to spores of *Bacillus subtilis* and closely related species. Submitted.
67. **Turnbough CL Jr. (2002).** Discovery of phage-displayed peptide ligands for
 10 species-specific detection of *Bacillus* spores. *J. Microbiol. Methods*, in press.
68. **Williams DD, Benedek O, and Turnbough CL Jr. (2002).** Peptide ligands for the detection of *Bacillus anthracis* spores. Submitted.
69. **Anthony SD, Gu M, Cowley SC, Leung WWS and Nano FE. (1991).**
 15 Transformation and allelic replacement in *Francisella* spp. *J. Gen. Microbiol.* **137**: 2697-2703.
70. **Berg JM, Mdluli KE, and Nano FE (1992).** Molecular cloning of the *recA* gene and construction of a *recA* strain of *Francisella novicia*. *Infect. Immun.* **60**:690-693.
71. **Weiss GA, Watanabe CK, Zhong A., Goddard A, and Sidhu SS. (2000).** Rapid
 20 mapping of protein functional epitopes by combinatorial alanine scanning. *Proc. Natl. Acad. Sci. USA* **97**: 8950-8954.
72. **Viti F, Nilsson F, Demartis S, Huber A, and Neri D (2000).** Design and use of phage display libraries for the selection of antibodies and enzymes. *Meth. Enzymol.*
 25 **326**:480-505.
73. **Schaffitzel C, Hanes J, Jermutus L, and Pluckthun A (1999).** Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. *J. Immunol. Meth.* **231**:119-135.
74. **Hanes J, Schaffitzel C, Knäppik A, and Pluckthun A (2000).** Picomolar
 30 affinity antibodies from a fully synthetic naïve library selected and evolved by ribosome display. *Nature Biotech.* **18**:1287-1292.

75. Wilson ds, Keefe AD, and Szostak JW (2001). The usc of mRNA display to select high-affinity protcin-binding pcptides. *Proc. Natl. Acad. Sci. USA* 98:3750-3755.
76. Zallauskiene L, Kang S, Brouillette CG, Lebowitz J, Arani RB, and Collawn JF (2000). Down-regulation of cell surface receptors is modulated by polar residues within the transmembrane domain. *Mol. Biol. Cell* 11:2643-2655

Amino acid	Shotgun codon	Possible substitutions
F	K (C/T) T	A/I/S/V
G	G (G/C) T	A/G
H	(G/C) (A/C) T	A/H/D/P
M	(A/G) (C/T) G	A/M/T/V
P	(G/C) C A	A/P
R	(G/C) (G/C) T	A/R/G/P
S	(G/T) C C	A/S
T	(A/G) C T	A/T
W	(G/T) (G/C) G	A/W/G/S
Y	(G/T) (A/C) T	A/Y/D/S

Table 1: Substitutions that allow random substitution of alanine at any position in an amino acid sequence (adapted from 71). These amino acid codons will be introduced into the identified peptide sequence obtained from the Negative/Positive selection strategy described.

CLAIMS

What is claimed:

- 1. An peptide the having the amino acid composition of SEQ ID NO: 2.**

ABSTRACT

Novel reagents capable of identifying, or aiding in the identification of, *Francisella* strains, such as, but not limited to,, but not limited to, *F. tularensis* and *F. novicida*, are disclosed. In addition, methods for the identification and isolation of the reagents are disclosed. In one embodiment the reagents are peptide sequences. The reagents may be used in diagnostic assays and kits to diagnose the presence of *Francisella* strains, such as, but not limited to,, but not limited to, *F. tularensis* and *F. novicida*. In addition the agents identified may be used as research tools for the study and characterization of *Francisella* strains, such as, but not limited to,, but not limited to, *F. tularensis* and *F. novicida*. The reagents identified may also be used to develop vaccines useful for protection against *Francisella* strains, such as, but not limited to,, but not limited to, *F. tularensis* and *F. novicida*.

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6

**binding of phage to Francisella strains by strain and phage
4 degrees C**





FIG. 7

**binding of phage to Francisella strains (mid log growth)
grown in different growth media**



Engler tularemia.ST25.txt
SEQUENCE LISTING

<110> Engler, Jeffrey
Escuyer, Vincent E.

<120> IDENTIFIATION OF REAGENTS FOR THE DIAGNOSIS AND STUDY OF
FRANCISELLA TULARENSIS

<130> P69085US00GO

<160> 5

<170> PatentIn version 3.2

<210> 1

<211> 22

<212> DNA

<213> artificial

<220>

<223> primer

<400> 1

gtatgggatt ttgctaaaca ac

22

<210> 2

<211> 12

<212> PRT

<213> phage display peptide sequence

<400> 2

Thr Ser Ile Thr Pro Trp Phe Phe Leu Ser Arg Pro
1 5 10

<210> 3

<211> 12

<212> PRT

<213> phage display peptide sequence

<400> 3

Leu Pro Ile Ser Asn Pro Leu Pro Ile Lys Arg Ser
1 5 10

<210> 4

<211> 12

<212> PRT

<213> phage display peptide sequence

<400> 4

Thr Gly Arg His Thr Pro Trp Pro His Phe Met Pro
1 5 10

<210> 5

<211> 12

<212> PRT

<213> artificial

Engler tularemia.ST25.txt

<220>

<223> negative control peptide

<400> 5

Ser Leu Phe Trp Thr Thr Pro Ile Pro Ser Phe Arg
1 5 10

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/022460

International filing date: 14 July 2004 (14.07.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/487,530
Filing date: 14 July 2003 (14.07.2003)

Date of receipt at the International Bureau: 06 September 2004 (06.09.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



Creation date: 03-28-2006
Indexing Officer: DNGUYEN8 - DANH NGUYEN
Team: OIPEBackFileIndexing
Dossier: 10564900

Legal Date: 01-17-2006

No.	Doccode	Number of pages
1	371P	3
2	SPEC	44
3	CLM	9
4	ABST	1
5	DRW	1
6	NPL	60

Total number of pages: 118

Remarks:

Order of re-scan issued on